---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-002193"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-23T23:22:40.648209+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma FY2024 revenue $34.9M (+45% YoY); net loss widens to $5.1M

## Summary
- Revenue $34.9M in FY2024, up 45% from $24.1M in FY2023; gross profit $10.7M.
- Net loss $5.1M vs $4.5M in FY2023; G&A expenses $16.5M, up from $13.1M.
- Completed ~$10M underwritten public offering for expansion of sales operations.
- Launched 13 new generic drugs; received Health Canada approval for oncology drug NIOPEG.
- Published PLpro inhibitor study in J. Med. Chem.; completed mouse model proof-of-concept for K1.1 mRNA.

## SEC filing metadata
- accession: 0001683168-25-002193
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316825002193/0001683168-25-002193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316825002193/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-002193
- JSON: https://secwatch.observer/filing/0001683168-25-002193.json
- Plain text: https://secwatch.observer/filing/0001683168-25-002193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.